Defining Quality Indicators for Best-Practice Management of Inflammatory Bowel Disease in Canada
Geoffrey C. Nguyen(Johns Hopkins Medicine), Jennifer Jones(Dalhousie University), Waqqas Afif, Shane Devlin, Gilaad G. Kaplan(University of Calgary), Brian Bressler(University of British Columbia), S E Gruchy(Dalhousie University), Cynthia H. Seow(University of Calgary), Sophie Plamondon(Université de Sherbrooke), Brian Yan(Western University), Liliana Oliveira(Ottawa Hospital), Karen Wong, Chadwick Williams
Cited by 57
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry
|Gastroenterology|2020|692
Rates of New or Missed Colorectal Cancers After Colonoscopy and Their Risk Factors: A Population-Based Analysis
|Gastroenterology|2007|627
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
|Gastroenterology|2015|478